search
Back to results

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Primary Purpose

Relapsed/Refractory AML

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Uproleselan
Placebo
Sponsored by
Apollomics Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Relapsed/Refractory AML focused on measuring AML

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. ≥18 years and ≤75 years in age
  2. AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis
  3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

    1. For relapse AML, it must be the first or second relapse, and remain untreated.
    2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
  4. No more than one prior stem cell transplant
  5. Has not received the chemotherapy regimen to be used for induction on this trial
  6. Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial

Exclusion Criteria:

  1. Patients with acute promyelocytic leukemia
  2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)
  3. Chronic myeloid leukemia with myeloid blast crisis
  4. Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture required)
  5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  6. Stem cell transplantation ≤4 months prior to dosing.
  7. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing
  8. Inadequate organ function.
  9. Abnormal liver function.
  10. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
  11. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
  12. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  13. Clinically significant cardiovascular disease.
  14. Major surgery within 4 weeks of dosing.

Sites / Locations

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeRecruiting
  • The First Affiliated Hospital of Zhejiang UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Uproleselan

Placebo (Saline, 0.9% Sodium Chloride)

Arm Description

Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation

Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation

Outcomes

Primary Outcome Measures

Overall survival
Time from the date of randomization into the study to the date of death.

Secondary Outcome Measures

Remission rate(rate of CR, CR/CRi and CR/CRh)
Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh
Duration of remission
Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.
Event-free survival
Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.
Rate of severe oral mucositis
Incidence of severe oral mucositis experienced in patients after treatment.

Full Information

First Posted
September 14, 2021
Last Updated
November 22, 2021
Sponsor
Apollomics Inc.
Collaborators
Zhejiang CrownMab Biotech Co. Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05054543
Brief Title
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Official Title
A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Recruiting
Study Start Date
October 18, 2021 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
February 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Apollomics Inc.
Collaborators
Zhejiang CrownMab Biotech Co. Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML
Detailed Description
This trial will enroll approximately 140 randomized subjects 18 through 75 years of age at the time of randomization with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy as described. Randomization will be done at trial entry at a 1:1 ratio, and will be stratified by age (<60, ≥60 years) and disease status (primary refractory/early relapse ≤6 months, late relapse>6 months) and prior HSCT status. Treatment assignment received at randomization will be maintained during all induction and consolidation cycles. This trial will have the following sequential phases: screening, baseline, induction treatment and count recovery, response assessment, consolidation treatment (if remission is achieved), and follow-up for relapse and survival assessment. Subjects not achieving remission will continue to be followed for long-term trial endpoints such as disease progression and survival. Blinding will be maintained until database lock. All subjects will be followed for long-term outcomes until death or withdrawal of consent.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsed/Refractory AML
Keywords
AML

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Uproleselan
Arm Type
Experimental
Arm Description
Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Uproleselan in combination with HiDAC/IDAC during consolidation
Arm Title
Placebo (Saline, 0.9% Sodium Chloride)
Arm Type
Placebo Comparator
Arm Description
Placebo in combination with mitoxantrone, etoposide and cytarabine (MEC) during induction; Placebo in combination with HiDAC/IDAC during consolidation
Intervention Type
Drug
Intervention Name(s)
Uproleselan
Other Intervention Name(s)
GMI-1271
Intervention Description
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Saline
Intervention Description
0.9% Sodium Chloride
Primary Outcome Measure Information:
Title
Overall survival
Description
Time from the date of randomization into the study to the date of death.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Remission rate(rate of CR, CR/CRi and CR/CRh)
Description
Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh
Time Frame
Up to 60 days
Title
Duration of remission
Description
Time from date of first documented remission to date of relapse or death from any cause, whichever occurs first.
Time Frame
Up to 3 years
Title
Event-free survival
Description
Time from date of randomization into the study to the date of treatment failure, relapse, or death from any cause; whichever occurs first.
Time Frame
Up to 3 years
Title
Rate of severe oral mucositis
Description
Incidence of severe oral mucositis experienced in patients after treatment.
Time Frame
Up to 254 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ≥18 years and ≤75 years in age AML diagnosed with ≥20% myeloid marrow blasts or peripheral blood blasts per WHO criteria(2008) at the time of initial diagnosis For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy. For relapse AML, it must be the first or second relapse, and remain untreated. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed. No more than one prior stem cell transplant Has not received the chemotherapy regimen to be used for induction on this trial Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial Exclusion Criteria: Patients with acute promyelocytic leukemia Acute leukemia of ambiguous lineage (biphenotypic leukemia) Chronic myeloid leukemia with myeloid blast crisis Active signs or symptoms of CNS involvement by malignancy (No lumbar puncture required) Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing. Stem cell transplantation ≤4 months prior to dosing. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing Inadequate organ function. Abnormal liver function. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min). Uncontrolled acute life-threatening bacterial, viral, or fungal infection. Clinically significant cardiovascular disease. Major surgery within 4 weeks of dosing.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhejiang CrownMab Ltd.
Phone
0571-83521933
Email
ClinicalTrialsChina@apollomicsinc.com
First Name & Middle Initial & Last Name or Official Title & Degree
Qian Li
Phone
0571-83521933
Email
Qian.Li@apollomicsinc.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jianxiang Wang, PhD
Organizational Affiliation
Institute of Hematology & Blood Diseases Hospital, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300020
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianxiang Wang, Phd
Phone
022-23909120
Email
wangjx@medmail.com.cn
Facility Name
The First Affiliated Hospital of Zhejiang University
City
Hangzhou
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Jin, PhD
Phone
057187236685
Email
jiej0503@zju.edu.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

We'll reach out to this number within 24 hrs